Work

Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps10586

Authors: Andrea M Gross, Andrea Baldwin, Eva Dombi, Pamela Wolters, Patricia Whitcomb, Marielle Holmblad, Staci Martin, Michael J. Fisher, AeRang Kim, Brian D. Weiss, Scott M. Paul, Wade Clapp, Kathleen Farrell, Michaele Smith, Joseph Fontana, Alessandra Brofferio, Seth M. Steinberg, Laurence A Doyle, Brigitte C. Widemann

Institutions: Children's National, National Cancer Institute, Leidos Biomedical Research Inc. (United States), Children's Hospital of Philadelphia, Cincinnati Children's Hospital Medical Center, Indiana University School of Medicine, National Institutes of Health, Center for Cancer Research

Language: English

Topic: Neurofibromatosis and Schwannoma Cases

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4251850211

Cites:

Cited by:

Related to: 10